<DOC>
	<DOCNO>NCT02498509</DOCNO>
	<brief_summary>Clinical Trial Evaluate Efficacy Safety CKD-342</brief_summary>
	<brief_title>Clinical Trial Evaluate Efficacy Safety CKD-342</brief_title>
	<detailed_description>A Randomized , Double-blind , Active-controlled , Multicenter phase 3 Clinical trial evaluate Efficacy Safety Concomitant Mometasone furoate Levocabastine HCl Perennial Allergic Rhinitis patient</detailed_description>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<mesh_term>Levocabastine</mesh_term>
	<criteria>1. male , female , Age : 13 year ( age limiation upper ) 2. subject experience perennial allergic rhinitis 1 year 3. subject identify allergen throughout year within 12 month 4. subject symptom moderate severe allergic rhinitis 5. subject record patient diary clinical trial period 6. subject agree keep environment clinical trial period 1 . Asthma 2 . Previous medical history screening ( Nasal polyp within previous two month , biopsy , ulcer , trauma , surgery , atrophic rhinitis , patient history drug rhinitis ) 3 . Patients untreated localized infection nasal mucosa 4 . Patients follow administration combination prohibit drug patient administer concomitant medication trial period expect inevitable 5 . Patients abnormal follow laboratory test result screen AST , ALT &gt; 2times upper limit normal screen Serum creatinine &gt; 1.5times upper limit normal screen 6 . Previous history acute severe chronic sinusitis within 30 day screen 7 . The continue use drug may affect efficacy Investigational product 8 . Start immunotherapy change doge within 1 month , screen 9 . If glaucoma cataract , herpes simplex , around eye 10 . Chronic obstructive pulmonary disease ( COPD ) 11. history hypersensitivity reaction treaty major component IP 12 . Pregnant woman , breast feeding woman woman childbearing potential must agree use appropriate contraception method 13 . Alcohol illegal drug abuse dependence patient 14. participation investigational maketed drug within 4weeks precede screen visit 15 . Patients participate clinical trial investigator 's discretion</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>